ARS Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

ARS Pharmaceuticals

12/05/2025 14:07

ARS Pharmaceuticals Inc SPRY.OQ SPRY.O is expected to show a rise in quarterly revenue when it reports  results on May 14 for the period ending March 31 2025

The San Diego California-based  company is expected to report revenue of $7.482 million, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for ARS Pharmaceuticals Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 1.8% in the last three months. ‚Äč

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $30.00‚Äč, above‚Äč its last closing price of $13.44. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.10
-0.14
0.49
Beat
450
Sep. 30 2024
-0.15
-0.15
-0.20
Missed
-35.6
Jun. 30 2024
-0.13
-0.12
-0.13
Missed
-11.4‚Äč
Mar. 31 2024
-0.12
-0.11
-0.11
Met
0
‚Äč‚ÄčDec. 31 2023
-0.11
-0.14
-0.07
Beat
50
Sep. 30 2023
-0.19
-0.18
-0.16
Beat
12.4‚Äč
Jun. 30 2023
-0.19
-0.17
-0.18
Missed
-3.6
Mar. 31 2023
-0.17
-0.17
-0.16
Beat
4.6

This summary was machine generated May 12 at 13:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)